Loading
A phase 1/2 trial of Fludarabine, Cyclophosphamide, Nivolumab in mesothelioma and ovarian cancer, run by TCR2 Therapeutics, active and no longer recruiting.
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer is a phase 1/2 interventional study registered as NCT03907852 by TCR2 Therapeutics, with 57 participants enrolled, started 2019-04-15 and due to reach its primary completion in 2024-11-19. Interventions recorded: gavo-cel, fludarabine, cyclophosphamide, Nivolumab, Ipilimumab. Conditions listed: Mesothelioma, Mesothelioma, Malignant, Mesothelioma; Pleura, Mesotheliomas Pleural. No results are recorded here; the registry entry is the source.
Shares Fludarabine, Cyclophosphamide, Ovarian cancer.
Shares Mesothelioma, Ipilimumab, Nivolumab, Small-cell lung cancer.
Shares Ipilimumab, Nivolumab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Ipilimumab, Nivolumab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Mesothelioma, Ovarian cancer, Non-small-cell lung cancer.
Shares Mesothelioma, Ipilimumab, Nivolumab.
Shares Fludarabine, Mesothelioma, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.